{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:12:51Z","timestamp":1791277971721,"version":"4.1.0"},"reference-count":153,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20180307150419435"],"award-info":[{"award-number":["JCYJ20180307150419435"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Incidence rates of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) are lower but more aggressive in children than in adults due to different biological and host factors. After the clinical application of tyrosine kinase inhibitor (TKI) blocking BCR\/ABL kinase activity, the prognosis of children with CML and Ph+ ALL has improved dramatically. Yet, off-target effects and drug tolerance will occur during the TKI treatments, contributing to treatment failure. In addition, compared to adults, children may need a longer course of TKIs therapy, causing detrimental effects on growth and development. In recent years, accumulating evidence indicates that drug resistance and side effects during TKI treatment may result from the cellular metabolism alterations. In this review, we provide a detailed summary of the current knowledge on alterations in metabolic pathways including glucose metabolism, lipid metabolism, amino acid metabolism, and other metabolic processes. In order to obtain better TKI treatment outcomes and avoid side effects, it is essential to understand how the TKIs affect cellular metabolism. Hence, we also discuss the relevance of cellular metabolism in TKIs therapy to provide ideas for better use of TKIs in clinical practice.<\/jats:p>","DOI":"10.3389\/fonc.2022.1072806","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T05:17:19Z","timestamp":1670303839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review"],"prefix":"10.3389","volume":"12","author":[{"given":"Chunmou","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2010.10.003","article-title":"Functions of B56-containing PP2As in major developmental and cancer signaling pathways","volume":"87","author":"Yang","year":"2010","journal-title":"Life Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.18.012502.083431","article-title":"Receptor kinase signaling in plant development","volume":"18","author":"Becraft","year":"2002","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1038\/s41598-020-60195-z","article-title":"Innate T-\u03b1\u03b2 lymphocytes as new immunological components of anti-tumoral \u201coff-target\u201d effects of the tyrosine kinase inhibitor dasatinib","volume":"10","author":"Barbarin","year":"2020","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181695","article-title":"Prognostic values of signal transducers activators of transcription in gastric cancer","volume":"39","author":"Zhang","year":"2019","journal-title":"Biosci Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"13734","DOI":"10.1038\/s41598-017-14033-4","article-title":"The src family kinase LCK cooperates with oncogenic FLT3\/ITD in cellular transformation","volume":"7","author":"Marh\u00e4ll","year":"2017","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5604\/17322693.968778","article-title":"Tyrosine kinase inhibitors in hematological malignancies","volume":"65","author":"Kosior","year":"2011","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205317","article-title":"Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease","volume":"21","author":"Scheijen","year":"2002","journal-title":"Oncogene"},{"key":"B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12943-018-0797-x","article-title":"Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges","volume":"17","author":"Butti","year":"2018","journal-title":"Mol Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7150\/jca.11893","article-title":"Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer","volume":"6","author":"Lampaki","year":"2015","journal-title":"J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u20132020)","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/gtc.12022","article-title":"Activity-based kinase profiling of approved tyrosine kinase inhibitors","volume":"18","author":"Kitagawa","year":"2013","journal-title":"Genes Cells"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-2473","article-title":"Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia","volume":"116","author":"Millot","year":"2005","journal-title":"Pediatrics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-380774","article-title":"How I treat childhood CML","volume":"119","author":"Andolina","year":"2012","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.06.003","article-title":"Current status of imatinib as frontline therapy for chronic myeloid leukemia","volume":"47","author":"Marin","year":"2010","journal-title":"Semin Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1038\/s41467-021-23097-w","article-title":"Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia","volume":"12","author":"Ochi","year":"2021","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28491","article-title":"Outcomes of children with chronic myeloid leukemia: A population-based cohort study","volume":"67","author":"Egan","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1001\/jama.285.21.2705-JFD10005-3-1","article-title":"From the food and drug administration","volume":"285","author":"Schwetz","year":"2001","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a children\u2019s oncology group phase 1 study","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: Results of children\u2019s oncology group trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia Chromosome\u2013like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126411","article-title":"Genomic analyses of pediatric acute lymphoblastic leukemia ph+ and ph-Like-Recent progress in treatment","volume":"22","author":"Kaczmarska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJM200004063421402","article-title":"Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"342","author":"Aric\u00f2","year":"2000","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1325","article-title":"Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005","volume":"28","author":"Aric\u00f2","year":"2010","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401939","article-title":"Children\u2019s cancer group trials in childhood acute lymphoblastic leukemia: 1983-1995","volume":"14","author":"Gaynon","year":"2000","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Semin Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e042814","DOI":"10.1136\/bmjopen-2020-042814","article-title":"Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"BMJ Open"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41467-020-20259-0","article-title":"Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem\/progenitor cells in chronic myelogenous leukemia","volume":"12","author":"Lei","year":"2021","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.039560","article-title":"Mutant BCR-ABL clones in chronic myeloid leukemia","volume":"96","author":"Mathisen","year":"2011","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.958465","article-title":"Ponatinib in the leukemia world: why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation","volume":"7","author":"Goodrich","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance","volume":"4","author":"Quentmeier","year":"2011","journal-title":"J Hematol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.aap8210","article-title":"LZTR1 is a regulator of RAS ubiquitination and signaling","volume":"362","author":"Bigenzahn","year":"2018","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2011.1062","article-title":"BCR-ABL- and ras-independent activation of raf as a novel mechanism of imatinib resistance in CML","volume":"39","author":"Hentschel","year":"2011","journal-title":"Int J Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/10428190903383427","article-title":"Advances in treatment of chronic myelogenous leukemia\u2013new treatment options with tyrosine kinase inhibitors","author":"Santos","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfu215","article-title":"A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity","volume":"143","author":"Talbert","year":"2015","journal-title":"Toxicol Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty","volume":"98","author":"Giona","year":"2013","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0707841","article-title":"Primary ovarian insufficiency associated with imatinib therapy","volume":"358","author":"Christopoulos","year":"2008","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200411113512024","article-title":"Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome","volume":"351","author":"Seshadri","year":"2004","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.04.022","article-title":"A metabolic roadmap for somatic stem cell fate","volume":"31","author":"Ly","year":"2020","journal-title":"Cell Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-092910-154237","article-title":"Aerobic glycolysis: meeting the metabolic requirements of cell proliferation","volume":"27","author":"Lunt","year":"2011","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160809","article-title":"Understanding the warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3291","article-title":"Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells","volume":"15","author":"Kominsky","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"DeBerardinis","year":"2008","journal-title":"Cell Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M105796200","article-title":"Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells","volume":"276","author":"Boren","year":"2001","journal-title":"J Biol Chem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0039","article-title":"Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-Positive cells","volume":"10","author":"Gottschalk","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208461","article-title":"Chronic myeloid leukaemia: an investigation into the role of bcr-abl-induced abnormalities in glucose transport regulation","volume":"24","author":"Barnes","year":"2005","journal-title":"Oncogene"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1021\/bi0474923","article-title":"Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis","volume":"44","author":"Dombrauckas","year":"2005","journal-title":"Biochemistry"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0914845107","article-title":"The alternative splicing repressors hnRNP A1\/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism","volume":"107","author":"Clower","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2015.11.020","article-title":"Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells","volume":"371","author":"Shinohara","year":"2016","journal-title":"Cancer Lett"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12943","article-title":"Tyrosine kinase inhibitors reduce glucose uptake by binding to an exofacial site on hGLUT-1: Influence on 18 f-FDG PET uptake","volume":"14","author":"Damaraju","year":"2021","journal-title":"Clin Transl Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1142086","article-title":"Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production","volume":"57","author":"Ko","year":"2016","journal-title":"Leukemia Lymphoma"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.493","article-title":"Erratum: Glucose transporter 1-mediated glucose uptake is limiting for b-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis","volume":"5","author":"Liu","year":"2014","journal-title":"Cell Death Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2146","article-title":"Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations","volume":"21","author":"Alvarez-Calderon","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.07.001","article-title":"Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes","volume":"155","author":"Damaraju","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01106","article-title":"Imatinib and dasatinib provoke mitochondrial dysfunction leading to oxidative stress in C2C12 myotubes and human RD cells","volume":"11","author":"Bouitbir","year":"2020","journal-title":"Front Pharmacol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellbi.2006.08.006","article-title":"Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro","volume":"30","author":"Hagerkvist","year":"2006","journal-title":"Cell Biol Int"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0086","article-title":"Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients","volume":"95","author":"Fitter","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br J Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","article-title":"Lipid metabolism reprogramming and its potential targets in cancer","volume":"38","author":"Cheng","year":"2018","journal-title":"Cancer Commun (Lond)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.07.007","article-title":"SREBP activity is regulated by mTORC1 and contributes to akt-dependent cell growth","volume":"8","author":"Porstmann","year":"2008","journal-title":"Cell Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2018.00055","article-title":"The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model","volume":"5","author":"Pouwer","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173666","article-title":"Imatinib improves insulin resistance and inhibits injury-induced neointimal hyperplasia in high fat diet-fed mice","volume":"890","author":"Pichavaram","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5580","article-title":"Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem","volume":"6","author":"Iurlo","year":"2015","journal-title":"Oncotarget"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc052500","article-title":"Imatinib and hyperlipidemia","volume":"353","author":"Gottardi","year":"2005","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1228928","article-title":"The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: A retrospective clinical study and in vitro assessment of lipid-genes transcription","volume":"58","author":"Ellis","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604946","article-title":"Time-dependent effects of imatinib in human leukaemia cells: A kinetic NMR-profiling study","volume":"100","author":"Klawitter","year":"2009","journal-title":"Br J Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.10295","article-title":"Real-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin","volume":"48","author":"Glunde","year":"2002","journal-title":"Magn Reson Med"},{"key":"B81","article-title":"Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death","volume":"63","author":"Griffin","year":"2003","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20123069","article-title":"Bioactive peptide VHVV upregulates the long-term memory-related biomarkers in adult spontaneously hypertensive rats","volume":"20","author":"Ju D-T","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/elsc.201700084","article-title":"In-line monitoring of amino acids in mammalian cell cultures using raman spectroscopy and multivariate chemometrics models","volume":"18","author":"Bhatia","year":"2017","journal-title":"Eng Life Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-2070-4","article-title":"Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression","volume":"73","author":"Li","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.603837","article-title":"Metabolism of amino acids in cancer","volume":"8","author":"Wei","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e283145","DOI":"10.1155\/2015\/283145","article-title":"Integration of mitochondrial targeting for molecular cancer therapeutics","volume":"2015","author":"Marchetti","year":"2015","journal-title":"Int J Cell Biol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trecan.2017.01.005","article-title":"Glutamine metabolism in cancer: Understanding the heterogeneity","volume":"3","author":"Cluntun","year":"2017","journal-title":"Trends Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.05.017","article-title":"Cellular fatty acid metabolism and cancer","volume":"18","author":"Currie","year":"2013","journal-title":"Cell Metab"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.2174\/1566524011313040005","article-title":"Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer","volume":"13","author":"Mat\u00e9s","year":"2013","journal-title":"Curr Mol Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2334","article-title":"SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival","volume":"19","author":"Hassanein","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2011.12.009","article-title":"Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in b cells","volume":"15","author":"Le","year":"2012","journal-title":"Cell Metab"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e0153226","DOI":"10.1371\/journal.pone.0153226","article-title":"Hypoxia-like signatures induced by BCR-ABL potentially alter the glutamine uptake for maintaining oxidative phosphorylation","volume":"11","author":"Sontakke","year":"2016","journal-title":"PloS One"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101410","article-title":"Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells","volume":"55","author":"Trinh","year":"2022","journal-title":"Mol Metab"},{"key":"B95","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11864-018-0532-2","article-title":"When to stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"19","author":"Laneuville","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nature20132","article-title":"LKB1 loss links serine metabolism to DNA methylation and tumorigenesis","volume":"539","author":"Kottakis","year":"2016","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3557","article-title":"Serine, glycine and one-carbon units: cancer metabolism in full circle","volume":"13","author":"Locasale","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.41.9.605","article-title":"Pathway of serine formation from carbohydrate in rat liver*","volume":"41","author":"Ichihara","year":"1955","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3709","article-title":"Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors","volume":"73","author":"Vazquez","year":"2013","journal-title":"Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/ng.890","article-title":"Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis","volume":"43","author":"Locasale","year":"2011","journal-title":"Nat Genet"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/science.1218595","article-title":"Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation","volume":"336","author":"Jain","year":"2012","journal-title":"Science"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/nature22056","article-title":"Modulating the therapeutic response of tumours to dietary serine and glycine starvation","volume":"544","author":"Maddocks","year":"2017","journal-title":"Nature"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2020.0144","article-title":"Insights into the mechanism of anticancer drug imatinib revealed through multi-omic analyses in yeast","volume":"24","author":"Taymaz-Nikerel","year":"2020","journal-title":"OMICS: A J Integr Biol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113443","article-title":"Metabolic plasticity is an essential requirement of acquired tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"12","author":"Mostazo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B105","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cmet.2018.10.013","article-title":"Quantitative analysis of the whole-body metabolic fate of branched-chain amino acids","volume":"29","author":"Neinast","year":"2019","journal-title":"Cell Metab"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-020518-114455","article-title":"Branched chain amino acids","volume":"81","author":"Neinast","year":"2019","journal-title":"Annu Rev Physiol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.12.011","article-title":"Emerging roles for branched-chain amino acid metabolism in cancer","volume":"37","author":"Sivanand","year":"2020","journal-title":"Cancer Cell"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/nature21052","article-title":"Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer","volume":"542","author":"Dey","year":"2017","journal-title":"Nature"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf5171","article-title":"Tissue of origin dictates branched-chain amino acid metabolism in mutant kras-driven cancers","volume":"353","author":"Mayers","year":"2016","journal-title":"Science"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/nature22314","article-title":"Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia","volume":"545","author":"Hattori","year":"2017","journal-title":"Nature"},{"key":"B111","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12885-016-2367-1","article-title":"Methionine-restricted diet inhibits growth of MCF10AT1-derived mammary tumors by increasing cell cycle inhibitors in athymic nude mice","volume":"16","author":"Hens","year":"2016","journal-title":"BMC Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20171048","article-title":"Eukaryotic-type serine\/threonine kinase mediated phosphorylation at Thr169 perturbs mycobacterial guanylate kinase activity","volume":"37","author":"Yadav G","year":"2017","journal-title":"Biosci Rep"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01189-2","article-title":"Folate metabolism: a re-emerging therapeutic target in haematological cancers","volume":"35","author":"Zarou","year":"2021","journal-title":"Leukemia"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S1631-0691(02)01533-0","article-title":"Roles of positive and negative feedback in biological systems","volume":"325","author":"Cinquin","year":"2002","journal-title":"Comptes Rendus Biol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091354","article-title":"Purine-metabolising enzymes and apoptosis in cancer","volume":"11","author":"Camici","year":"2019","journal-title":"Cancers"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1080\/15257770.2015.1125001","article-title":"Mitochondrial purine and pyrimidine metabolism and beyond","volume":"35","author":"Wang","year":"2016","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/BF00963915","article-title":"Effect of undernutrition on some enzymes involved in the salvage pathway of purine nucleotides in different regions of developing rat brain","volume":"8","author":"Vanella","year":"1983","journal-title":"Neurochem Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/YCO.0000000000000388","article-title":"Lesch-nyhan syndrome and its variants: examining the behavioral and neurocognitive phenotype","volume":"31","author":"Harris","year":"2018","journal-title":"Curr Opin Psychiatry"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv047","article-title":"Regulation of mammalian nucleotide metabolism and biosynthesis","volume":"43","author":"Lane","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2009.01.002","article-title":"The molecular determinants of de novo nucleotide biosynthesis in cancer cells","volume":"19","author":"Tong","year":"2009","journal-title":"Curr Opin Genet Dev"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.6b00356","article-title":"Metabolite profiling of the plasma and leukocytes of chronic myeloid leukemia patients","volume":"15","author":"Karl\u00edkov\u00e1","year":"2016","journal-title":"J Proteome Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.04.054","article-title":"Understanding specificity in metabolic pathways\u2013structural biology of human nucleotide metabolism","volume":"396","author":"Welin","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00040-16","article-title":"Phosphoribosyl diphosphate (PRPP): Biosynthesis, enzymology, utilization, and metabolic significance","volume":"81","author":"Hove-Jensen","year":"2017","journal-title":"Microbiol Mol Biol Rev"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B125","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/bs.acr.2019.03.004","article-title":"Immunometabolism: A new target for improving cancer immunotherapy","volume":"143","author":"Guo","year":"2019","journal-title":"Adv Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nri2922","article-title":"Immunometabolism: an emerging frontier","volume":"11","author":"Mathis","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-42118-6_6","article-title":"Metabolic features of cancer treatment resistance","volume":"207","author":"Viale","year":"2016","journal-title":"Recent Results Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.09.001","article-title":"Metabolic reprogramming of immune cells in cancer progression","volume":"43","author":"Biswas","year":"2015","journal-title":"Immunity"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2017.04.029","article-title":"Fire and water: Tumor cell adaptation to metabolic conditions","volume":"356","author":"Cairns","year":"2017","journal-title":"Exp Cell Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B131","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.it.2014.12.005","article-title":"Fatty acid metabolism in the regulation of T cell function","volume":"36","author":"Lochner","year":"2015","journal-title":"Trends Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1807291","article-title":"Expression signature, prognosis value, and immune characteristics of siglec-15 identified by pan-cancer analysis","volume":"9","author":"Li","year":"2020","journal-title":"Oncoimmunology"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184056","article-title":"Chronic myeloid leukemia in children: Immune function and vaccinations","volume":"10","author":"Suttorp","year":"2021","journal-title":"J Clin Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0849","article-title":"The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses","volume":"14","author":"Christiansson","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108821","article-title":"Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors","volume":"109","author":"Hong","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6294","article-title":"Therapeutic immune monitoring of CD4+CD25+ T cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"14","author":"Lu","year":"2017","journal-title":"Oncol Lett"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1713","article-title":"Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-\u03baB and akt signaling pathways","volume":"11","author":"Appel","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2129-9","article-title":"The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells","volume":"67","author":"D\u00f6rfel","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04606-9","article-title":"Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment","volume":"100","author":"Kong","year":"2021","journal-title":"Ann Hematol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2022.2090549","article-title":"The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation","volume":"63","author":"Xu","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0611","article-title":"Implication of the autologous immune system in BCR\u2013ABL transcript variations in chronic myelogenous leukemia patients treated with imatinib","volume":"75","author":"Clapp","year":"2015","journal-title":"Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children\u2019s oncology group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61023-5","article-title":"Low bone density and decreased inhibin-B\/FSH ratio in a boy treated with imatinib during puberty","volume":"372","author":"Mariani","year":"2008","journal-title":"Lancet"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.008359","article-title":"Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib","volume":"94","author":"Schmid","year":"2009","journal-title":"Haematologica"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24121","article-title":"Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia: Imatinib retards growth in children with CML","volume":"59","author":"Rastogi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24397","article-title":"Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH\/IGF-1 axis: Imatinib and growth hormone deficiency","volume":"60","author":"Narayanan","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22945","article-title":"Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy: Growth hormone deficiency and imatinib","volume":"56","author":"Hobernicht","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"B153","doi-asserted-by":"publisher","first-page":"e2014028","DOI":"10.4084\/mjhid.2014.028","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"Abruzzese","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1072806\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T05:17:24Z","timestamp":1670303844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1072806\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":153,"alternative-id":["10.3389\/fonc.2022.1072806"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1072806","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"article-number":"1072806"}}